U.S. Medical Equipment Stock News

Silvaco Group just watched its stock slide 11.2% to US$7.65 in the first full session after earnings, even as the headline result was the first clean step toward profitability. Behind the selling, the company posted Q2 revenue of US$17.8m and moved into a small non GAAP profit, helped by an 86.8% gross margin and tighter cost control. The market is trading the long history of losses and recent share volatility. The quarter itself tells a different story, with the real tension now between fear...

Nuvation Bio stock jumped about 8% to US$6.60 after its Q2 earnings, a sharp move for a small oncology player that investors largely treat as a long haul drug platform story. The headline this quarter is not a surprise profit. It is the pressure on the income statement as the company leans into commercial and research spending, with a Q2 net loss of US$62.8m on US$31.7m of revenue. For you as a shareholder, the question now is whether that widening loss is tolerable in exchange for the...

Valhi stock barely flinched after earnings, slipping only 0.7% to US$15.89, even though the quarter marked a sharp break from its recent loss making record. The company posted Q2 basic earnings per share of US$0.78 on revenue of US$627.6m, a clear swing back into the black after a run of weak trailing results. For a stock that has been priced cheaply on sales and wrestling with unprofitable trailing figures, a profitable quarter changes the conversation. The key question now is whether this...

Northern Oil and Gas came into this earnings print looking like a value story that had stalled, with the stock down over the past three months despite double digit gains in the last month. The 6.5% jump to about US$21.60 after the Q2 release shows investors reacting to one thing above all else: free cash flow swung sharply higher, with adjusted EBITDA and cash generation rebounding from a weak Q1 and putting real weight behind the long term thesis. Love Northern Oil and Gas' free cash flow...

In recent weeks, Lockheed Martin’s Skunk Works, the U.S. Air Force Test Pilot School and partners used an AI agent on the X-62 VISTA to autonomously execute 27 live air intercepts using real-time sensor data, while the U.S. government awarded a seven-year undefinitized contract action modification for up to US$53.86 billion to accelerate PAC-3 MSE interceptor production. Together, these advances in sensor-driven autonomy and large-scale missile procurement highlight Lockheed Martin’s role at...

US Foods Holding stock barely flinched on the headline, with a move of about 1.8% despite one of its strongest quarters in years. The market saw another green day for a food distributor. The earnings told a sharper story. Q2 adjusted earnings per share landed at US$1.44 with record adjusted EBITDA of US$604 million and a 5.7% adjusted EBITDA margin. That margin performance sits at the heart of this print. The stock came into results already on a strong multi month run, so today’s restrained...

Kingsway stock jumped 12.8% to US$10.24 after the Q2 print, a sharp move for a company that has spent years wrestling with losses. The headline this time is margin and profit relief. Consolidated net income flipped to a US$0.2 million profit from a loss a year ago, while adjusted earnings before interest, tax, depreciation and amortisation reached US$5.2 million. That is the story traders are chasing today. For investors thinking beyond a single quarter, the question is how this early profit...

Investors pushed KLA up 2.5% to about US$198 in the session after earnings, even though the stock had slipped around 10% over the past month. The move reflects a simple reality. The market had been uneasy about a premium P/E and a stock trading well above a recent discounted cash flow estimate. The new quarter just put hard numbers under the long term thesis. The headline is straightforward. KLA reported record quarterly revenue of US$3.66b and delivered strong non GAAP earnings per share...

Surrozen jumped 18.4% to US$25.62 after its latest earnings, a sharp move for a biotech that still sits on deep losses. Traders are reacting to the headline surge, while the longer view remains far more complicated. The company continues to post sizeable losses on a small revenue base, and the stock already trades on a rich price to sales multiple versus other biotechs. For long term investors, the real story is not today’s pop. It is how Surrozen plans to fund itself, confront negative...

VAALCO Energy went into this earnings print with a muted three month share performance, and the stock then jumped 7.6% to US$5.55 once investors saw the numbers. The quarter headline is simple. A company that had just reported a loss of US$93.9 million in Q1 swung to net income of US$42.4 million in Q2 on revenue of US$135.2 million. For an oil and gas producer that has been wrestling with losses over the past year, that kind of earnings swing grabs attention. The rest of the report explains...

Nexstar Media Group stock closed up 3.1% at US$193.78, which indicates traders responded positively to the headline. The core story is in the cash flow. Quarterly revenue reached roughly US$2.0b and adjusted free cash flow was US$238m, more than double a year earlier, as the TEGNA deal, political advertising and major sports events contributed to higher broadcast and distribution results. In the short term, this appears to be a relief rally after a volatile 90-day period. Over a longer...

Gen Digital stock came into this earnings print on a strong run, with the share price up about 29% over the past three months and another 3.8% added today. The market is cheering a cyber security business that just reported double digit revenue growth in Q1 and lifted its full year outlook. That is the short term story. The longer term question for you is whether this quarter represents a durable earnings and margin reset for Gen Digital or just a positive chapter in a choppy profit history...

Proto Labs, Inc. reported past second-quarter 2026 results showing sales of US$149.34 million and net income of US$9.15 million, with earnings per share roughly doubling year over year; it also updated full-year 2026 guidance and filed a US$29.68 million shelf registration tied to an ESOP-related common stock offering. The combination of stronger profitability, higher full-year revenue growth guidance of 8%–10%, and new ESOP-related share issuance highlights both improving operating...

Earlier this month, Dianthus Therapeutics reported second-quarter 2026 results showing a wider net loss of US$50.22 million and basic loss per share of US$0.90, alongside a six-month net loss of US$91.05 million. On the same day, the company unveiled DNTH312, a first-in-class bifunctional fusion protein combining claseprubart and TACI to target both aC1s and BAFF/APRIL, highlighting an effort to address severe autoimmune diseases through a single molecule with extended intellectual property...

QuidelOrtho came into this print looking like a classic deep value healthcare stock, with the share price already under pressure and the P/S ratio sitting near 0.3x. The market’s verdict on Q2 was brutal. The stock dropped about 25% in the first session after earnings, as investors focused on continued losses and balance sheet strain rather than the low headline valuation. The headline from the quarter is clear. Reported revenue was about US$631m and adjusted EBITDA reached US$129m, yet...

ESAB stock slipped 2.8% to US$91.86 into the close, yet the real story sits in the income statement. The market latched onto a softer quarterly earnings per share print while looking past a heavier pressure point. Net profit over the last twelve months sits at US$196.3m on more than US$3.0b of revenue, which leaves a thinner cushion than many investors in industrial tools and welding equipment might prefer. The sentiment reckoning today is about margins. Trailing net margin has compressed to...

Palladyne AI went into this earnings print as a richly valued, high growth defense AI stock, and the market reaction so far looks muted. The share price edged up about 2% to US$5.99 after the release, which is hardly a conviction move for a company trading on roughly 24x trailing sales. The headline this quarter is simple. Palladyne AI posted record quarterly revenue of about US$5.8m while still reporting a net loss of about US$12.3m. Revenue momentum is clear, but the size of the loss keeps...

E.W. Scripps stock jumped 12.5% to about US$3.32 in regular trading, a sharp move for a broadcaster that has sat under pressure with a 90 day return that is down 26.8%. The spark was not a clean earnings beat. The headline was a large goodwill and intangible asset impairment of roughly US$1.1b that turned quarterly earnings per share into a steep loss. In the very short term traders are reacting to relief that the balance sheet reset is now out in the open. Long term investors are weighing...

El Pollo Loco Holdings just served up a 7% drop in the stock to US$15.16, even as the company posted one of its cleaner quarters in recent memory. Net income for Q2 2026 came in at US$12.8m on revenue of US$129.6m, with basic earnings per share of US$0.43. In the short term, the market is focusing on the red on the screen. Over a longer horizon, the key question is whether a roughly 13x P/E on a business with improved trailing margins and cautious earnings forecasts represents a reset or an...

The market slammed Arrow Electronics on the earnings release, with the stock dropping about 8% on the day. That looks like an emotional reaction to a headline move rather than what is actually happening in the business. Arrow just printed roughly US$10.0b in Q2 revenue and more than US$5 in basic earnings per share, both well ahead of where the company sat a year ago. The real story is a sharp step up in profitability, not a collapse. This sets up a clear sentiment gap between the screen and...

Medicine worth an estimated £480m is reportedly wasted each year in England, which puts a harsh spotlight on how prescriptions are written, supplied and used. That kind of leakage can reshape where money flows across healthcare technology. Investors watching digital health and pharmacy platforms may not want to sit this out. This article looks at three Healthcare Technology Providers stocks exposed to this debate and explains why they might matter for your watchlist. The stocks covered below...

PureCycle Technologies stock added 4.9% to close at US$7.21 heading into the first full trading day after its Q2 2026 release. That is a confident move for a company that just reported another heavy quarterly loss. The market is cheering the balance sheet story instead of the income statement. The headline this quarter is liquidity. PureCycle raised about US$432m in fresh equity and convertible notes and finished the quarter with US$236.9m in total liquidity, plus an undrawn US$200m revolving...

Cryoport stock quietly entered this earnings day with a flat week and a slightly soft month, yet it closed up 2.8% at US$15.12 once the numbers were released. That move came against a mixed backdrop for a company still priced at a premium P/S multiple and not yet profitable. The main headline is straightforward. Cryoport reported Q2 revenue of US$49.0m and, importantly for a loss-making life sciences logistics business, delivered positive adjusted earnings before interest, tax, depreciation...

Puma Biotechnology stock jumped 9.7% to US$8.91 after earnings, a sharp move for a small oncology player that investors usually treat with caution. The immediate catalyst was simple: the company stayed profitable and lifted full year guidance, powered by NERLYNX net product revenue of US$53.6m and Q2 net income of US$8.2m. The bigger story is less about one quarter and more about whether this profit trend can coexist with forecasts for weaker earnings in the years ahead. That tension between...